You are here

  • Home
  • Archive
  • Volume 77, Issue 8
  • Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)

Citation Tools

Article menu

This article has a correction. Please see:

Download PDFPDF
Clinical and epidemiological research
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Charles P, Terrier B, Perrodeau É for the French Vasculitis Study Group, et al
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)
Annals of the Rheumatic Diseases 2018;77:1143-1149.